Serial Entrepreneur and Biotech Leader Thomas Saylor Joins Business Advisory Board of OncoSpherix

by Oncospherix | May 23, 2022 | General

OncoSpherix is pleased to announce that Thomas Saylor has joined the company’s business advisory board. Mr. Saylor has served as CEO of six emerging biotech companies in the U.S., Europe and Asia, leading enterprises that cover drug development, pharmaceutical...

Internationally Renowned Medical Oncologist Dr. Harvey Golomb Joins Clinical Advisory Board of OncoSpherix

by Oncospherix | May 5, 2022 | General

OncoSpherix is pleased to announce that Dr. Harvey Golomb has joined the Clinical Advisory Board of OncoSpherix.  Dr. Golomb’s recognition as a preeminent leader in oncology began early in his career, as reflected by his election in 1990 as President of the American...

OncoSpherix’s Chief Scientific Officer Dr. Erwin Van Meir Honored with Endowed Professorship for Brain Cancer Research

by Oncospherix | Apr 20, 2022 | General

Dr. Erwin Van Meir is the inaugural David Hart White Endowed Professorship for Brain Cancer Research at the National Cancer Institute-designated O’Neal Comprehensive Cancer Center at the University of Alabama Birmingham. Dr. Van Meir’s research illuminates how genetic...

OncoSpherix’s CEO will Give Keynote Address at Drug Discovery Nexus East Coast 2022 on April 21, 2022

by Oncospherix | Apr 20, 2022 | General

Dr. Margaret K Offermann will be speaking on Thursday, April 21, 2022 from 11:30 AM -12:00 PM Eastern time at the Drug Discovery Nexus East Coast 2022 conference that will be held virtually.  The title of her presentation is “Improving Design and Interpretation...

Oncospherix’s Chief Scientific Officer Dr. Erwin Van Meir Publishes Study that Sheds Light on HIF-Regulated Genes that Contribute to Tumor Invasion and Metastasis in Eye Melanoma

by Oncospherix | Mar 4, 2022 | General

Dr. Erwin Van Meir and colleagues published a study identifying HIF-regulated genes (P4HA1 and P4HA2) that contribute to the invasion of uveal melanoma cells into surrounding tissues. Importantly, this process could be blocked using a HIF inhibitor, KCN1, that works...

OncoSpherix’s Founding Scientist and Board of Directors’ member Binghe Wang, PhD, is Honored by his Selection as a National Academy of Inventors Fellow

by Oncospherix | Feb 28, 2022 | General

OncoSpherix is pleased to announce that Dr. Binghe Wang has been elected as a fellow at the National Academy of Inventors. Dr. Wang is a renowned synthetic medicinal chemist with expertise in drug design, delivery, and molecular recognition. He is a founding scientist...